


REVIEWS


EDITORIALS


2. King CS, Nathan SD. “Should all patients with IPF, even those with more than moderate impairment, be treated with nintedanib or pirfenidone?” YES. Chest. 2016;150(2):273-275


BOOK CHAPTERS AND BOOKS


2. Shlobin OA, Nathan SD. Rare ILD and PH. For Pulmonary Hypertension and Interstitial lung disease. Edited by Robert P. Baughman, Roberto G. Carbone and Steven D. Nathan.


ORIGINAL RESEARCH ABSTRACTS & PRESENTATIONS TO INTERNATIONAL MEETINGS


PRESENTATIONS AT NATIONAL/INTERNATIONAL MEETINGS


5. “Xenotransplantation: Comparison with Human Psychosocial Selection Criteria”
   Jane Harrison, LCSW, CCTSW; Society for Transplant Social Work, San Diego, California.


